Dr. Gaurav Chandra, MD,MBA, COO, and DirectorEnzolytics is revolutionizing drug development and disease prevention through the power of AI and monoclonal antibody technology. Their groundbreaking approach to infectious diseases has the potential to transform the healthcare industry and improve the lives of countless individuals.
The Company’s groundbreaking AI platform accelerates drug development by expediting the identification, synthesis, and screening of potential candidates. Its revolutionary approach has already demonstrated impressive results, cutting the time it takes to develop HIV monoclonal antibodies from 20 years to a mere two and a half weeks.
The platform’s capabilities extend beyond rapid drug development, encompassing genomic surveillance and monitoring of virus epidemiology. Tracking viruses and their mutations globally ensures the monoclonal antibodies being developed are primed for the most potent and specific attacks.
“We are excited about the fight against COVID-19. With our global analysis of 2.8 million SARS-CoV-2 isolates, we have successfully identified 19 conserved sites that remain unchanged despite the emergence of numerous virus variants. This breakthrough gives us confidence that a monoclonal antibody targeting these sites would remain effective against any future mutations, providing a much-needed weapon in our ongoing battle against COVID-19,” says Dr. Gaurav Chandra, COO and Director of Enzolytics.
Enzolytics is well-prepared with a robust AI platform poised to tackle the next pandemic using a proactive and data-driven strategy. The platform can identify conserved sites in different viruses and predict future mutations, which can assist the scientific community in preparing for and responding to global health threats.
The primary distinction of this innovative process for creating fully human monoclonals is the starting point – from human “immune-B cells” obtained from humans who have recovered successfully from a “natural” infection. The Company uses human immune-B cells to create effective antibodies that target specific sites on the virus. These antibodies have a lower risk of causing immune responses and retain their natural affinity and specificity. Additionally, they offer a new level of potency and resilience against mutations. For instance, the company's primary HIV antibody is 50 times more potent than existing monoclonal antibodies developed by the National Institutes of Health (NIH). Targeting conserved sites that remain unchanged over time, these antibodies can maintain their efficacy in the face of viral evolution.
A groundbreaking development from Enzolytics is the creation of a topical antibody for COVID-19, designed for administration as a nasal spray. This innovation uses IgA antibodies, which target the mucosal membranes in the nasal area—the primary point of contact for the virus. This nasal spray could potentially serve as a preventive measure for the general population, with the added advantage of not being affected by any virus mutations.
We have made great strides in combating COVID-19. By studying 2.8 million SARS-CoV-2 samples, we have identified 19 reliable areas unaffected by mutations. The antibody is Universal, Broadly neutralizing, durable, and unaffected by mutations. This achievement is significant as it will result in the developing of a monoclonal antibody that can enhance our capacity to combat future mutations and improve our fight against this virus and future viruses.
An innovative approach, bolstered by its technology and exceptional team, offers real hope in the fight against infectious diseases and the ever-present threat of future pandemics. Leveraging the power of AI and cutting-edge antibody research, Enzolytics aims to redefine how we combat and protect ourselves from the invisible enemies that threaten global health.
